Biogen plummets 32% after its Alzheimer's therapy fails to win support from FDA advisory committee
Published
Nov 09 2020 at 1:35 PM GMT
Key
Points
Points
- The committee voted 8-1 that data from a Biogen study evaluating patients with mild Alzheimer's was not enough to show efficacy.
Tags
-
Posted in Business
Trending
Stats
- Published Nov 9, 2020 1:35 PM GMT